RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Pharming Group Stock

Pharming Group AAQS 2024

Pharming Group AAQS

4

Ticker

PHARM.AS

ISIN

NL0010391025

WKN

A1H65A

Pharming Group has a current AAQS of 4.

A high AAQS can be seen as a positive indicator that the company is developing successfully.

Investors can assume that the company is on a good path to generate profits.

On the other hand, it is important to consider the AAQS of the stock Pharming Group in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.

In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.

Pharming Group Aktienanalyse

What does Pharming Group do?

Pharming Group NV was founded in 1988 and is headquartered in the Netherlands. The company specializes in the development and marketing of medical products for the treatment of rare diseases. Its business model is based on the discovery and development of recombinant proteins. These proteins are produced using genetic engineering techniques and serve as the foundation for the development of therapeutic products in various areas. The main focus of Pharming Group NV is the manufacturing and marketing of biopharmaceuticals. The company has a wide range of products used in the treatment of rare diseases, including C1-esterase inhibitor preparations used for acute attacks in hereditary angioedema. Another important product of Pharming Group NV is recombinant human lysozyme. It is used in the treatment of cystic fibrosis and has shown promising results as a therapeutic approach. Pharming Group NV also collaborates closely with various research and development organizations to develop new products and expand knowledge in the medical industry. The company has experienced impressive growth in recent years. In 2019, Pharming Group NV achieved a revenue of 149 million euros. A significant portion of this revenue was generated through the sale of C1-esterase inhibitor preparations. Pharming Group NV has also made a name for itself in the international market. The company has branches in the USA and Europe and works closely with international regulatory authorities to ensure smooth approval and marketing of its products. Overall, Pharming Group NV has a promising future as it continues to invest in research, development, and expansion of its product portfolio. By focusing on the development of products for the treatment of rare diseases, Pharming Group NV positions itself as a leading company in the medical industry and contributes to improving the lives of people worldwide. Pharming Group ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Frequently Asked Questions about Pharming Group stock

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Pharming Group stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Pharming Group

Our stock analysis for Pharming Group Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Pharming Group Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.